The Human Variable 

The Target Readiness Index™ (TRI) introduces a state-dependent framework for CRISPR target prioritization across ME/CFS, Long COVID, Lyme disease, and autoimmune conditions including lupus, type 1 diabetes, Hashimoto’s, and Sjögren’s.

SymCas™ is a flare prediction model for POTS, Lyme disease, ME/CFS, Long COVID and relapsing chronic conditions. It identifies symptom patterns over time to detect early instability and support proactive care.

The true U.S. burden of Lyme disease is estimated at 5 - 7 million Americans, according to CYNAERA’s US-CCUC™ 2026 prevalence model, substantially higher than the roughly 400,000 to 500,000 diagnoses recorded annually. By accounting for underdiagnosis, chronic illness, and fragmented surveillance, this paper reframes Lyme disease as a major chronic illness burden rather than a narrowly counted regional infection.

Personalized CRISPR Remission™ for ME/CFS explores customized, individualized gene-editing strategies based on immune state, environmental factors, and neuroimmune instability to enable state-dependent remission in infection-associated chronic conditions. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, multi-system condition. Personalized CRISPR Remission™ for MECFS is not limited to one editing event or one delivery paradigm.

A state-dependent CRISPR Remission™ framework for systemic lupus erythematosus (SLE) integrating multiomics, AI, environmental modeling (VitalGuard™), and US-CCUC™ prevalence correction to improve timing, safety, and economic outcomes in autoimmune precision medicine.

CDF-Lyme™ is a multi-system diagnostic framework for Lyme disease that identifies immune, neurological, autonomic, and functional patterns beyond traditional testing.